Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib

BACKGROUND: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. METHODS: Data of 554 patients with mRCC who...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Myung Soo, Chung, Ho Seok, Hwang, Eu Chang, Jung, Seung Il, Kwon, Dong Deuk, Hwang, Jun Eul, Bae, Woo Kyun, Park, Jae Young, Jeong, Chang Wook, Kwak, Cheol, Song, Cheryn, Seo, Seong Il, Byun, Seok-Soo, Hong, Sung-Hoo, Chung, Jinsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291404/
https://www.ncbi.nlm.nih.gov/pubmed/30546281
http://dx.doi.org/10.3346/jkms.2018.33.e325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291404/
https://www.ncbi.nlm.nih.gov/pubmed/30546281
http://dx.doi.org/10.3346/jkms.2018.33.e325

Ejemplares similares